Clinical trial / 2015
Combined glucosamine and chondroitin reduced 2-year knee joint space narrowing compared to placebo, but did not significantly reduce pain above placebo.
A 2-year trial randomized 605 participants with knee osteoarthritis to once-daily glucosamine sulfate (1500 mg), chondroitin sulfate (800 mg), both supplements, or placebo. After adjusting for structural disease progression factors, the combination group showed a statistically significant reduction in 2-year JSN versus placebo (mean difference 0.10 mm, 95% CI 0.002 mm to 0.20 mm; p=0.046), whereas single treatments showed no significant structural effect. All four groups had reduced knee pain over the first year, with no significant between-group differences (p=0.93). Overall, 34 (6%) participants reported possibly-related adverse medical events over 2 years.
- Study type
- Double-blind randomised placebo-controlled clinical trial
- Who was studied
- 605 participants aged 45-75 years with chronic knee pain and medial tibio-femoral compartment narrowing
- What was measured
- Joint space narrowing (JSN) over 2 years and maximum knee pain over 1 year
THE PAPER
Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens.
Fransen M, Agaliotis M, Nairn L, Votrubec M, Bridgett L, Su S, Jan S, March L, Edmonds J, Norton R, Woodward M, Day R, LEGS study collaborative group. Ann Rheum Dis, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.